Navigation Links
Menon Biosensors Accurately Detects Biological Pathogen in More Than 2,200 Samples
Date:12/19/2013

SAN DIEGO, Dec. 19, 2013 /PRNewswire/ -- Menon Biosensors, a molecular biochemistry company that provides DNA analysis for the diagnosis of biological pathogens, today announced that its nuclear magnetic resonance (NMR) technology successfully detected Yersinia pestis, also known as the plague, in more than 2,200 samples without any false positives or negatives.

In the studies conducted over a six year period, Menon Biosensors' platform technology was able to detect the presence of Yersinia pestis in water, air, blood, sputum, urine and stool. Concentrations were as low as from 1 colony-forming unit (CFU) per sample, with a limit of detection in the range of 1-100 CFU/mL and a dynamic range of 1-10^9 CFU/mL.  Analyzing low level samples required minimal preparation time, and including measurement was completed in less than one hour. Menon Biosensors is currently conducting validation studies at Scripps La Jolla in Clostridium difficile (C. difficile) and Mycobacterium tuberculosis complex (TB), with data expected in early 2014.

"Having reviewed the new diagnostic technology, process and assay data generated using Menon Biosensors' technology in identifying several well-known pathogens, I believe this technology provides a foundation to achieve a more facile, next-generation DNA diagnostic platform," said John Spinosa, M.D., Ph.D., pathologist at Scripps La Jolla. "Menon Biosensors' technology has significant implications in molecular biochemistry diagnostic applications for improving patient care and outcomes in an affordable and streamlined manner."

Added David Schlotterbeck, chairman of Menon Biosensors, "This data demonstrates that our technology can more accurately and rapidly detect a biological pathogen compared to currently available tests, and with higher sensitivity. With our upcoming data in C. difficile and TB, we plan to demonstrate that it can be easily and accurately applied to different pathogens with assays developed in less than six months."

Menon Biosensors' platform technology has been validated through multiple studies with the U.S. government's Biodefense Program. In these studies, conducted in more than 3,000 samples over a six year period, the technology demonstrated greater than 99 percent accuracy. The tests were conducted in the presence of interferants and near neighbors of the pathogens to be detected. 

By providing accurate results in less than one hour from the time a sample is collected, Menon Biosensors' platform technology allows medical professionals to quickly treat a pathogen with the appropriate and potentially life-saving therapeutic. Current diagnosis techniques for many pathogens require several hours to multiple days for accurate detection, depending on the pathogen, which limits treatment options early in the patient's care.

The platform technology is portable and available in both manual and continuous configurations.  Operating the portable system requires less than 10 watts of electricity, which enables operation off of a battery.  The system size is less than a cubic foot and weighs less than 10 pounds.  Reagents used in the assays are lyophilized, allowing them to be stored at room temperature for more than one year without jeopardizing the effectiveness of the test. 

About Menon Biosensors

Menon Biosensors is a molecular biochemistry company that provides DNA analysis for the diagnosis of biological pathogens. Menon Biosensors' microfluidics and NMR platform technology provides superior sensitivity and specificity and minimizes sample preparation, thereby providing best in class sample-to-answer pathogen detection.  The technology has been validated by respected third parties in more than 3,000 samples over six years.


'/>"/>
SOURCE Menon Biosensors
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Biosensors Reports Financial Results for the Second Quarter and First Half of Fiscal Year 2014
2. Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2014
3. Biosensors Reports Financial Results for Fiscal Year 2013
4. Biosensors Completes Spectrum Dynamics Assets Acquisition
5. Biosensors to Acquire Assets of Spectrum Dynamics
6. Frost & Sullivan Acknowledges that PKCs Biosensors are Expected to Become the New Industry Standard in Pathogen Testing
7. Biosensors Reports Financial Results for the Third Quarter of Fiscal Year 2013
8. Biosensors Reports Strong Sales and Profitability in the First Quarter of Fiscal Year 2013
9. New Data Suggests Abbotts High Sensitive Troponin Test May Help Doctors More Accurately Diagnose Heart Attacks in Women
10. Study Demonstrates Glysure Systems Ability to Accurately Measure Blood Glucose Levels in the ICU
11. Independent Study Published in Clinical Infectious Diseases Highlights the Importance of Antimicrobial Removal Systems in Blood Culture to Rapidly and Accurately Aid in the Diagnosis of Sepsis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... Improvements Act of 1976, as amended ("HSR"), with respect ... Nasdaq: CPXX ) expired effective June 24, ... As previously announced on May 31, 2016, Jazz Pharmaceuticals ... which Jazz Pharmaceuticals has commenced a tender offer for ...
(Date:6/24/2016)... , June 24, 2016  Consumers have ... and regulators/payers have placed more emphasis on patient ... patient support programs in the pharmaceutical industry have ... medications. Consequently, pharmaceutical companies are focusing on becoming ... are providing products and services that improve health. ...
(Date:6/24/2016)... 2016   Bay Area Lyme Foundation , ... Center for Tick Borne Illness , Harvard Medical ... Hacking Medicine, University of California, Berkeley, and the ... five finalists of Lyme Innovation , the ... 100 scientists, clinicians, researchers, entrepreneurs, and investors from ...
Breaking Medicine Technology:
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... ... to fertility once they have been diagnosed with endometriosis. These women need a ... they also require a comprehensive approach that can help for preservation of fertility ...
(Date:6/25/2016)... Aliso Viejo, California (PRWEB) , ... June 25, 2016 , ... ... preset to fit their specific project," said Christina Austin - CEO of Pixel Film ... all fully customizable and all within Final Cut Pro X . Simply select ...
(Date:6/25/2016)... ... ... Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and Mental ... exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took place ... BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive an ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda ... orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including ... accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. ...
Breaking Medicine News(10 mins):